Unmatched Data, Unrivalled Diversity

What makes this collaboration unique is the scale and diversity of our local population, and the close relationship between the Trust and the University serving it. We have hundreds of thousands of local residents, speaking more than 60 languages.
This diversity enriches and enhances our ability to discover solutions that can work in London and the world.

Currently there are over 32,000 patients from the local community actively involved in clinical research programmes, and in terms of scale, Barts Life Sciences is home to some of the largest clinical trials in the UK. The insights from these unique data sets can – and already are – being used to help drive the creation of new solutions which will aid the reduction of health inequalities locally, nationally and around the world.

Centre for Public Engagement

Queen Mary is home to the Centre for Public Engagement, working to further embed public engagement into the fabric of the university.

The Centre for Public Engagement funds over 50 public engagement, community engagement and patient involvement projects a year, training, supporting, recognising and rewarding staff and students who work in an engaged way.

Delivering personalised care

We have access to unrivalled level of data – our ambition is to build on this and become a leading centre for genomics and precision healthcare. We are already working together to deliver this with organisations such as Genomics England and East London Genes and Health England.

Barts Life Sciences is currently working in partnership with Genomics England on its 100,000 genomes project. Hosted at Queen Mary, this will enable medical science advances through unlocking the power of DNA data, transforming the lives of NHS patients and their families.

The East London Genes & Health programme is a longitudinal study of people of Bangladeshi and Pakistani ethnicity within the East London community. Findings of the study will provide information on various health conditions that affect the population at large, and drive precision-based treatments for conditions such as heart disease and diabetes, transforming health outcomes locally and worldwide.

“The sequencing of 100,000 whole genomes marks an extraordinary UK achievement that is transforming the application of genomics in our NHS.”

Professor Sir Mark Caulfield

Queen Mary University of London and Chief Scientistat Genomics England

“The sequencing of 100,000 whole genomes marks an extraordinary UK achievement that is transforming the application of genomics in our NHS.”

Professor Sir Mark Caulfield

Queen Mary University of London and Chief Scientistat Genomics England

Multiple teams, one focus – transform healthcare

From renowned academics to frontline clinicians, we are a team of diverse organisations working together to advance the healthcare of the future.

Barts Life Sciences already have well established partnerships with local, national and international organisations, such as UCL Partners, Greater London Authority, Capital Enterprise, Med City, the Alan Turing Institute and NESTA which are being harnessed to help advance innovations within life sciences and AI. We also want to facilitate exciting collaborations with the best partners, life sciences organisations, entrepreneurs and start-ups from around the world, to continue to drive and deliver scientific advancements.

Space to innovate

More than 2.5 million sq ft of land is already being used for exciting life sciences activity in Whitechapel, and we are currently investing to expand this space even further, creating University Enterprise Zones to enable drug discovery start-ups and businesses to continue to drive innovation. There is also an opportunity to expand into a further 1 million sq ft of potential land in the area to create much-needed space for life sciences companies to grow and scale within the capital. We are actively looking for partners to build their visions and develop their innovations from our home.

If you are looking to solve the biggest medical problems and revolutionise patient outcomes, join us.